A Phase 2 interventional study of Helicobacter pylori eradication therapy in HELICOBACTER PYLORI INFECTIONS and Gastrointestinal Disease, sponsored by Mashhad University of Medical Sciences. Completed at 2 sites in Iran, Islamic Republic of. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2025-05-15.
Sponsored by Mashhad University of Medical Sciences · Phase 2, Interventional, and Treatment
548 studies on the registry are indexed under Gastrointestinal Diseases; 101 are open to participants now.
This study's enrollment of 60 is below the median of 80 across 388 interventional studies indexed under Gastrointestinal Diseases.
Browse Gastrointestinal Diseases studies →Mashhad University of Medical Sciences is the lead sponsor of 92 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
12 grams of egg yolk powder containing about 2 grams of antibody twice a day for 2 weeks along with usual antibiotic treatment including OAC or omeprazole (40 mg/day), clarithromycin (1000 mg/day) and amoxicillin (2000 mg/day).
Biological: Helicobacter pylori eradication therapy
normal egg yolk powder without IgY in the amount of 12 grams 2 times a day for 2 weeks along with usual antibiotic treatment OAC or omeprazole (40 mg/day), clarithromycin (1000 mg/day) and amoxicillin (2000 mg/day)
12 grams of egg yolk powder containing about 2 grams of antibody twice a day for 2 weeks along with usual antibiotic treatment including OAC or omeprazole (40 mg/day), clarithromycin (1000 mg/day) and amoxicillin (2000 mg/day).
Respiratory urea level (UBT) higher than cut off 50
This test is performed with the help of a diagnostic kit. After oral ingestion of a capsule containing labeled carbon and the patient's exhalation into the kit, the amount of urea breathed in is determined by the device. A UBT value greater than 50 means Helicobacter pylori infection.
Time frame: Determination of respiratory urea (UBT) at the beginning of the study and 8 weeks after the start of the intervention
Examining the patient's clinical symptoms including: abdominal pain, nausea, vomiting and bloating.
Based on the scoring of gastrointestinal symptoms (GSRS) in such a way that the score is calculated as follows: the number of participants with reduced abdominal pain: 0 (no symptoms), 1 (mild means the presence of tolerable symptoms), 2 (moderate means discomfort and interference) in normal activities), 3 (severe means inability to perform normal activities) -- the number of participants with reduced gastrointestinal symptoms: 0 (absence of nausea), 1 (temporary and short periods of nausea), 2 (frequent nausea) and long-term without vomiting), 3 (persistent nausea and frequent vomiting) -- the number of participants with reduced bloating: 0 (no bloating), 1 (short-term and temporary bloating), 2 (long-term but tolerable bloating), 3 (severe flatulence and interference in social functioning)
Time frame: During the treatment period for 4 weeks from the beginning of the intervention.
Plan to share: Undecided
Ran from Dec 2023 to primary completion in Dec 2024, 12 months.
Of 23 phase 2 interventional studies under Gastrointestinal Diseases, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 46. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mashhad University of Medical Sciences